By Morris James Mass Torts Attorneys Matthew R. Fogg and Keith E. Donovan
If you or a loved one was diagnosed with cutaneous T-cell lymphoma (CTCL) while taking Dupixent, you may be wondering whether it is still possible to file a lawsuit. For many patients and families, the answer is yes — but legal deadlines are firm, and the window to act will not stay open indefinitely.
This article explains what you need to know about timing, what affects your deadline, and why reaching out to an attorney sooner rather than later is in your best interest.
A statute of limitations is a legal deadline for filing a lawsuit. Once that deadline passes, courts will generally refuse to hear the case, regardless of how serious the injury was or how strong the evidence is. This is not a technicality that can be worked around after the fact — it is a hard cutoff, and missing it typically means losing your right to compensation permanently.
In Delaware, patients generally have two years to file a Dupixent lawsuit. Other states set their own deadlines for personal injury, product liability, and other lawsuits, which is one reason it is important to speak with an attorney who can evaluate the specific rules that apply to your situation.
What matters most right now is this: the clock is already running, and the only way to know exactly how much time you have is to get a legal assessment of your case.
Many people are surprised to learn that the legal clock does not necessarily start running on the day of a CTCL diagnosis. In fact, for many patients, the clock may start later — and understanding this could be the difference between having a viable claim and missing your window entirely.
The law in many states recognizes that patients cannot always know right away that a drug caused their illness. In those states, the clock may not start until you knew, or had reason to know, that Dupixent may have been connected to your diagnosis. This is especially relevant for CTCL patients, because the cancer closely resembles eczema and is frequently misdiagnosed. As we have explained in our article on how Dupixent may have hidden a CTCL diagnosis, many patients did not learn of a potential connection until long after their diagnosis.
Whether any exceptions apply to your situation depends on the specific facts of your case and the laws of your state. Do not assume time has run out, and do not assume you have more time than you think. Our Dupixent Lawsuits attorneys can tell you exactly where you stand.
Even if your deadline has not yet passed, waiting creates real problems that can affect the strength of your case.
Medical records get archived and become harder to obtain. Pharmacy histories take longer to reconstruct. Witnesses become harder to locate. The evidence most critical to a Dupixent CTCL claim is most accessible now, not a year from now. These cases also take time to build properly — thorough investigation and expert medical review are required before a claim can be filed. The sooner you reach out, the more we can do for you.
You may be eligible if you took Dupixent for eczema, asthma, or another condition and were later diagnosed with CTCL or another T-cell malignancy. Families who lost a loved one following a Dupixent-related CTCL diagnosis may also have grounds to file a wrongful death claim. For a full overview of eligibility criteria, see our guide on who may be eligible to file a Dupixent lymphoma lawsuit.
Patients and families are filing Dupixent CTCL lawsuits in courts across the country, and the number of claims is expected to grow significantly as more patients learn about the connection between Dupixent and cancer.
The scientific and regulatory record supporting these cases has built steadily. Studies published in 2024 and 2025 found that Dupixent users faced a significantly elevated risk of developing CTCL. In March 2025, the FDA added Dupixent to its FAERS quarterly safety signal report, specifically citing cutaneous T-cell lymphoma as a serious concern requiring evaluation. Legal deadlines do not pause while litigation develops, and if you have been waiting to see how the cases unfold, the time to act is now.
Patients who developed CTCL while taking Dupixent may be entitled to compensation for:
Every case is different, and the value of a claim depends on the specific facts, including the severity of the diagnosis, the duration of Dupixent use, and the impact on quality of life. Our attorneys can give you an honest assessment once they understand your situation.
Morris James LLP is actively reviewing Dupixent CTCL cases on behalf of patients and families across the country. We handle every case with personal attention, and we work on a contingency fee basis, which means there is no cost to you unless we recover compensation on your behalf. Your initial consultation is also free so you can find out more and decide the best next steps for you and your family — no fee and no obligation to call us.
If you or a family member was diagnosed with CTCL after taking Dupixent, please do not wait. The deadlines are real, and the sooner you speak with an attorney, the better we can protect your rights.
Call us at 302.655.2599 or contact us online for a free, confidential consultation.
